This treatment was different. It felt like a fog lifted, allowing me to process my experiences without being overwhelmed. For the first time in over a decade, I can sleep peacefully, connect with my loved ones, and feel present in my own life. It gave me hope when I thought none was left.
Jill,35
Recent Posts
At Sunstone Therapies, we believe healing goes deeper than the surface. While traditional oncology focuses on physical treatments, many patients still struggle with the psychological and emotional challenges of cancer. Our mission is to address the whole patient, which is why we created the 2Dose Study. This clinical trial, led by Dr. Manish Agrawal, builds on our initial study where 80% of participants experienced a greater than 50% reduction in depressive symptoms. The 2Dose Study will explore whether psilocybin is more effective than an active placebo and if two doses are better than one. The trial is open to people with all stages of cancer, not just advanced disease.
A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.
In psychedelic therapy clinical research, setting clear expectations is paramount. Transparent communication about potential disappointments can significantly reduce anxiety and foster a more grounded, trusting, and ultimately, healing journey for participants.